The company said net sales rose 27% to $1.76 billion for fiscal 2025 Q1, which ended September 30, 2024, and organic sales grew 31%. It cited higher volume in August 2023 as reflecting the lapping of the cyberattack as a driver of the increase.

1. 01

   The company said net sales rose 27% to $1.76 billion for fiscal 2025 Q1, which ended September 30, 2024, and organic sales grew 31%. It cited higher volume in August 2023 as reflecting the lapping of the cyberattack as a driver of the increase.

2. 02

   Clorox said gross margin rose 740 basis points to 45.8% from 38.4% in Q1. It said diluted EPS came in at $0.80, up from $0.17, and adjusted EPS came in at $1.86, up from $0.49. Diluted EPS reflected a 94 cent per share charge from the sale of the Better Health VMS business.

3. 03

   Clorox said it completed the divestiture of its entire Better Health VMS business on September 10, 2024. The company said it recorded a one-time after tax charge of $118 million in the first quarter of fiscal 2025, Q1. The divested brands include Natural Vitality, NeoCell, Rainbow Light and RenewLife.

4. 04

   Clorox said it updated its fiscal 2025 diluted EPS outlook to $5.17 to $5.42 from $4.95 to $5.20, and its adjusted EPS outlook to $6.65 to $6.90 from $6.55 to $6.80. It said it continues to expect net sales to be flat to down 2%.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.